



## Rüdiger Müller

### **Kontakt**

Rüdiger Müller

### **Bereiche**

Rheumatologie

## Publikationen (36)

Heinimann K, von Kempis J, Sauter R, Schiff M, Sokka-Isler T, Schulze-Koops H, Müller R. Long-Term Increase of Radiographic Damage and Disability in Patients with RA in Relation to Disease Duration in the Era of Biologics. Results from the SCQM Cohort. *J Clin Med* 2018; 7

Walker U, Müller R, Jaeger V, Theiler R, Forster A, Dufner P, Ganz F, Kyburz D. Disease activity dynamics in rheumatoid arthritis: patients' self-assessment of disease activity via WebApp. *Rheumatology (Oxford)* 2017; 56:1707-1712.

Alpizar-Rodriguez D, Gabay C, Courvoisier D, Lamacchia C, Mahler M, Roux-Lombard P, Von Mühlennen I, Walker U, Kyburz D, Zufferey P, Ciurea A, Dudler J, Möller B, Müller R, Finckh A. Female hormonal factors and the development of anti-citrullinated protein antibodies in women at risk of rheumatoid arthritis. *Rheumatology (Oxford)* 2017; 56:1579-1585.

Rein P, Müller R. Treatment with Biologics in Rheumatoid Arthritis: An Overview. *Rheumatology and Therapy* 2017; 4:247-261.

Rein P, Müller R. Treatment with Biologics in Rheumatoid Arthritis: An Overview. *Rheumatol Ther* 2017; 4:247-261.

Müller R, Graninger W, Sidiropoulos P, Goger C, von Kempis J. Median time to low disease activity is shorter in tocilizumab combination therapy with csDMARDs as compared to tocilizumab monotherapy in patients with active rheumatoid arthritis and inadequate responses to csDMARDs and/or TNF inhibitors: sub-analysis of the Swiss and Austrian patients from the ACT-SURE study. *Clin Rheumatol* 2017; 36:2187-2192.

Müller R, Graninger W, Sidiropoulos P, Goger C, von Kempis J. Median time to low disease activity is shorter in tocilizumab combination therapy with csDMARDs as compared to tocilizumab monotherapy in patients with active rheumatoid arthritis and inadequate responses to csDMARDs and/or TNF inhibitors: sub-analysis of the Swiss and Austrian patients from the ACT-SURE study. *Clin Rheumatol* 2017; 36:2187-2192.

Popp F, Benecke U, Fischer S, von Kempis J, Koeger P, Müller R. Blue-Finger-Syndrome and Tofacitinib - Case Report. *Clinical Image: Annals of Clinical Case Reports* 2017; 2

Popp F, Fischer S, Kempf W, von Kempis J, Welcker M, Müller R. Granuloma Annulare, Drug-Induced Lupus and - Case Report. *Clinical Image: Annals of Clinical Case Reports* 2017; 2

Alpizar-Rodriguez D, Bas S, Gascon D, Lamacchia C, Roux-Lombard P, Lauper K, Nissen M, Courvoisier D, Gabay C, Mahler M, Zufferey P, Brulhart L, Müller R, Möller B, Dudler J, Ciurea A, Walker U, Von Mühlennen I, Kyburz D, Finckh A. The prevalence of anticitrullinated protein antibodies increases with age in healthy individuals at risk for rheumatoid arthritis. *Clin Rheumatol* 2017

Müller R, von Kempis J, Spaeth M, Schiff M, Schulze-Koops H, Haile S, Finckh A, Kaegi T, Reshiti N. Does addition of glucocorticoids to the initial therapy influence the later course of the disease in patients with early RA? Results from the Swiss prospective observational registry (SCQM). *Clin Rheumatol* 2016; 36:59-66.

Müller R, Gengenbacher M, Richter S, Dudler J, Möller B, von Kempis J. Change from subcutaneous to intravenous abatacept and back in patients with rheumatoid arthritis as simulation of a vacation: a prospective phase IV, open-label trial (A-BREAK). *Arthritis Res Ther* 2016; 18:88.

Müller R. Postoperative Faszien dehiscenz unter kombinierter Immunmodulation mit Methotrexat, Prednison und Abatacept. *Swiss Medical Forum* 2016; 15:114-115.

Müller R, von Kempis J, Haile S, Schiff M. Effectiveness, tolerability, and safety of subcutaneous methotrexate in early rheumatoid arthritis: A retrospective analysis of real-world data from the St. Gallen cohort. *Semin Arthritis Rheum* 2015; 45:28-34.

Müller R, Schiff M, Kaegi T, Finckh A, Haile S, Schulze-Koops H, von Kempis J, Swiss Clinical Quality Management (SCQM) physicians. The new 2010 ACR/EULAR criteria as predictor of clinical and radiographic response in patients with early arthritis. *Clin Rheumatol* 2014; 34:51-9.

Müller R, Renner C, Gabay C, Cassata G, Lohri A, Hasler P. The advent of biosimilars: challenges and risks. *Swiss Med Wkly* 2014; 144:w13980.

Schiff M, von Kempis J, Goldblum R, Tesser J, Müller R. Rheumatoid arthritis secondary non-responders to TNF can attain an efficacious and safe response by switching to certolizumab pegol: a phase IV, randomised, multicentre, double-blind, 12-week study, followed by a 12-week open-label phase. *Ann Rheum Dis* 2014; 73:2174-7.

Müller R, Kaegi T, Finckh A, Haile S, Schulze-Koops H, von Kempis J, on behalf of the SCQM physicians. Is radiographic progression of late-onset rheumatoid arthritis different from young-onset rheumatoid arthritis? Results from the Swiss prospective observational cohort. *Rheumatology (Oxford)* 2013

Müller R. Tumor necrosis factor- $\alpha$  inhibition in radiographic and non-radiographic axial spondyloarthritis: results from a large observational cohort. *Arthritis Rheum* 2013; 2013:3096-3106.

Ciurea A, Weber U, Boonen A, Dougados M, van der Heijde D, Michel B, Nissen M, Müller R, Weiss B, Tamborrini G, Rufibach K, Stekhoven D, Kissling R, Beyeler B, Dudler J, Bernhard J, Exer P, Scherer A, Rheumatologists of the Swiss Clinical Quality Management Program for Axial Spondyloarthritis. Tumor necrosis factor  $\alpha$  inhibition in radiographic and nonradiographic axial spondyloarthritis: results from a large observational cohort. *Arthritis Rheum* 2013; 65:3096-106.

Müller R, Maier R, Hoschler K, Zambon M, Ludewig B, Herrmann M, Schulze-Koops H, von Kempis J. Efficient boosting of the antiviral T cell response in B cell-depleted patients with autoimmune rheumatic diseases following influenza vaccination. *Clin Exp Rheumatol* 2013; 31:723-30.

Zeidler J, Mittendorf T, Müller R, von Kempis J. Biologic TNF inhibiting agents for treatment of inflammatory rheumatic diseases: dosing patterns and related costs in Switzerland from a payers perspective. *Health Econ Rev* 2012; 2:20.

Müller R, Schett G, von Kempis J, Sheriff A, Maihöfner C, Kern P, Franz S, Munoz L, Winkler S, Vogt B, Herrmann M. Detection of low level cryoglobulins by flow cytometry. *Cytometry A* 2012; 81:883-7.

Müller R. *Clinical Trials in Rheumatology - 2. Auflage*. Heidelberg: Springer, 2011. ISBN 978-1-4471-2869-4.

Müller R, Sheriff A. Scoring adult-onset Still's disease. *J Rheumatol* 2010; 37:2203-4.

Weber C, Voll R, Schett G, Burkhardt H, Müller R, Distler J, Graef D, Mielenz D, Sehnert B, Englbrecht M, Haslbeck M, Füllrohr B. Antibodies to the endoplasmic reticulum-resident chaperones calnexin, BiP and Grp94 in patients with rheumatoid arthritis and systemic lupus erythematosus. *Rheumatology (Oxford)* 2010; 49:2255-63.

Müller R, von Kempis J. *Clinical Trials in Rheumatology*. Heidelberg: Springer, 2009. ISBN 978-1-84996-383-1.

Müller R, von Kempis J. *Rheuma-Drugfinder 2010*. 2010

Manea M, Müller R, Dejica D, Sheriff A, Schett G, Herrmann M, Kern P. Increased expression of CD154 and FAS in SLE patients' lymphocytes. *Rheumatology international* 2009; 30:181-185.

Di Comite G, Corti A, Sabbadini M, Rovere-Querini P, Voll R, Herrmann M, Müller R, Aiello P, Baldissera E, Lolmede K, Marinosci A, Rossi C, Manfredi A. Circulating chromogranin A reveals extra-articular involvement in patients with rheumatoid arthritis and curbs TNF-alpha-elicited endothelial activation. *Journal of leukocyte biology* 2009; 85:81-7.

Herman S, Müller-Ladner U, Neumann E, Gelse H, Hueber A, Redlich K, Zwerina J, Krönke G, Müller R, Schett G. Induction of osteoclast-associated receptor, a key osteoclast costimulation molecule, in rheumatoid arthritis. *Arthritis and rheumatism* 2008; 58:3041-50.

Müller R, Sheriff A, Gaipf U, Wesselborg S, Lauber K. Attraction of phagocytes by apoptotic cells is mediated by lysophosphatidylcholine. *Autoimmunity* 2007; 40:342-4.

Müller R, Skapenko A, Wendler J, Schuch F, Kalden J, Schulze-Koops H. MHC class II expression on myeloid cells inversely correlates with disease progression in early rheumatoid arthritis. *Rheumatology (Oxford, England)* 2007; 46:931-3.

Munoz L, Herrmann M, von der Mark K, Rödel F, Poschl E, Brachvogel B, Müller R, Baum W, Pausch F, Frey B, Gaipf U. The role of annexin A5 in the modulation of the immune response against dying and dead cells. *Current medicinal chemistry* 2007; 14:271-7.

Müller R, Skapenko A, Grunke M, Wendler J, Stuhlmüller B, Kalden J, Schulze-Koops H. Regulation of myeloid cell function and major histocompatibility complex class II expression by tumor necrosis factor. *Arthritis and rheumatism* 2005; 52:451-60.

Geffin R, Wolf D, Müller R, Hill M, Stellwag E, Freitag M, Sass G, Scott G, Baur A. Functional and structural defects in HIV type 1 nef genes derived from pediatric long-term survivors. *AIDS research and human retroviruses* 2000; 16:1855-68.

## Projekte (29)

### **Finch 302 Gilead**

*Klinische Forschung - 24.05.2017 - 26.09.2018*

*Abgeschlossen*

### **BIOBIO**

*Klinische Forschung - 14.02.2017 - 16.08.2018*

*Abgeschlossen*

### **BI1199.214 Sencis**

*Klinische Forschung - 09.08.2016 - 08.09.2017*

*Abgeschlossen*

### **BAY16277 RISE**

*Klinische Forschung - 13.05.2016 - 28.04.2019*

*Abgeschlossen*

### **SpA: AIN 457F2320**

*Klinische Forschung - 05.08.2015 - 16.08.2018*

*Abgeschlossen*

### **aScore: LONG-TERM EXPERIENCE WITH ABATACEPT SC IN ROUTINE CLINICAL**

*Klinische Forschung - 06.05.2015 - 06.10.2017*

*Abgeschlossen*

### **Fibromyalgie: A Randomized, Double-Blind, Placebo- and Active-Controlled Study of DS-5565 for Treatment of Pain Associated with Fibromyalgia**

*Klinische Forschung - 16.11.2014 - 31.05.2017*

*Abgeschlossen*

### **M13-375SpOA: A Multicenter, Randomized, Double-Blind, Study Comparing the Efficacy and Safety of**

*Klinische Forschung - 09.09.2014 - 07.04.2017*

*Abgeschlossen*

### **PsoA: A phase III, randomized, double-blind, placebo-controlled multicenter**

*Klinische Forschung - 20.08.2014 - 16.08.2018*

*Abgeschlossen*

**ABreak: Abatacept Study to omit weekly subcutaneous injections in RA patients during holiday BREAK**

*Klinische Forschung - 07.08.2014 - 07.12.2014*

*Abgeschlossen*

**RICE: An open label, randomized study to compare the efficacy of Certolizumab pegol (CZP) plus a dynamic or fixed dose treatment strategy in patients with Rheumatoid Arthritis, a phase II study**

*Klinische Forschung - 07.06.2014 - 31.08.2018*

*Abgeschlossen*

**BREVAS: A Phase 3, multi-center, multinational, randomized, double-blind Study to evaluate the efficacy and safety of Belimumab (HGS1006) in combination with Azathioprine for the maintenance of remission in Wegener's Granulomatosis and Microscopic Polyangiitis**

*Klinische Forschung - 07.11.2013 - 16.03.2017*

*Abgeschlossen*

**Digital Ulceration (CAP): a multicenter prospective cohort study using Nailfold Videocapillaroscopy and other factors to determine the risk of developing Digital Ulceration in patients with Systemic Sclerosis**

*Klinische Forschung - 11.07.2012 - 11.07.2012*

*Abgeschlossen*

**PALACE 3: Efficacy and Safety Study of Apremilast to Treat Active Psoriatic Arthritis**

*Klinische Forschung - 11.07.2012 - 22.02.2017*

*Abgeschlossen*

**FOCUS von Capillaroscopic Ulcer index in Systemic sclerosis**

*Klinische Forschung - 11.07.2012 - 28.07.2015*

*Abgeschlossen*

**Evaluation spezifischer Kollagendegradations-Biomarker im Serum und im Urin von Patienten mit einer rheumatoiden Arthritis**

*Klinische Forschung - 11.07.2012 - 11.07.2012*

*Automatisch geschlossen*

**Establishment of a Swiss national biological sample collection (SCQM-Biobank) coupled to the Swiss Clinical Quality Management cohort of patients with rheumatic diseases**

*Klinische Forschung - 11.07.2012 - 11.07.2012*

*Automatisch geschlossen*

**Prediction of early non response to anti-TNF and methotrexate combination therapy in rheumatoid arthritis patients eligible to first line anti-TNF treatment based on gene expression analysis of whole blood**

*Klinische Forschung - 25.07.2011 - 25.07.2012*

*Abgeschlossen*

**Evidence**

*Klinische Forschung - 07.10.2010 - 14.07.2011*

*Abgeschlossen*

**AdActa**

*Klinische Forschung - 23.09.2010 - 14.11.2011*

*Abgeschlossen*

**ESBA-Trial**

*Klinische Forschung - 08.08.2010 - 08.11.2008*

*Abgeschlossen*

**Go-More**

*Klinische Forschung - 08.04.2010 - 08.11.2010*

*Abgeschlossen*

**ATN 103**

*Klinische Forschung - 08.03.2010 - 08.11.2010*

*Abgeschlossen*

**Evaluation einer Strategie zur Früherkennung der Rheumatoiden Arthritis**

*Grundlagenforschung - 08.02.2010 - 08.01.2015*

*Automatisch geschlossen*

**Studie zum Ansprechverhalten auf die Impfung gegen die Pandemie mit der Influenza A (H1N1v, Schweinegrippe) bei Patienten mit rheumatischen Erkrankungen Arthritis**

*Grundlagenforschung - 08.12.2009 - 08.05.2010*

*Abgeschlossen*

**Prospective, observational trial in early Rheumatoid Arthritis (RA) patients exploring a possible relationship between expression of MHC class II and the prognosis of the disease (expression of MHC class II as a prognostic factor)**

*Klinische Forschung - 01.09.2009 - 01.09.2010*

*Automatisch geschlossen*

**Studie zur myeloiden Zellfunktion als prädiktiver Marker in der frühen rheuma-toiden Arthritis**

*Grundlagenforschung - 08.08.2009 - 08.01.2013*

*Abgeschlossen*

**Act-Sure Trial**

*Klinische Forschung - 08.06.2009 - 08.03.2010*

*Abgeschlossen*

**APRIL**

*Klinische Forschung - 08.06.2009 - 08.07.2010*

*Abgeschlossen*

---

Kantonsspital St.Gallen

Rorschacher Strasse 95

CH-9007 St.Gallen

T: +41 71 494 11 11

[support.forschung@kssg.ch](mailto:support.forschung@kssg.ch)